Videos

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain the misconception that cheaper biosimilars automatically lead to lower costs due to pharmacy benefit manager (PBM) spread pricing, while also highlighting major PBM trends toward increased transparency, value-based care, and efforts to reduce prescription costs.

Here are the top 5 biosimilar articles for the week of June 9, 2025.

Here are the top 5 biosimilar articles for the week of June 2, 2025.

Here are the top 5 biosimilar articles for the week of May 26, 2025.

Elena Wolff-Holz, MD, discussed the rationale and safety surrounding the automatic substitution of biosimilars at the pharmacy level, as well as common misconceptions about these medications.

Here are the top 5 biosimilar articles for the week of May 19, 2025.

Here are the top 5 biosimilar articles for the week of May 12, 2025.

Elena Wolff-Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access due to lower costs, and a possible lower immunogenicity profile.

Here are the top 5 biosimilar articles for the week of May 5, 2025.

Here are the top 5 biosimilar articles for the week of April 28, 2025.

Here are the top 5 biosimilar articles for the week of April 14, 2025.

Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable efficacy and safety data while noting challenges in global patient recruitment and regulatory navigation.

Here are the top 5 biosimilar articles for the week of April 7, 2025.

Here are the top 5 biosimilar articles for the week of March 31, 2025.

Here are the top 5 biosimilar articles for the week of March 24, 2025.

Here are the top 5 biosimilar articles for the week of March 17, 2025.

Here are the top 5 biosimilar articles for the week of March 10, 2025.

Here are the top 5 biosimilar articles for the week of March 3, 2025.

Here are the top 5 biosimilar articles for the week of February 24, 2025.

Here are the top 5 biosimilar articles for the week of February 17, 2025.

Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for greater payer trust in oncologists’ treatment decisions.

Here are the top 5 biosimilar articles for the week of February 10, 2025.

Here are the top 5 biosimilar articles for the week of February 3, 2025.

Josh Canavan, PharmD, head of pharmacy at RazorMetrics, recommends key educational resources for biosimilars, and emphasizes the extensive research conducted before pharmacy benefit managers (PBMs) add medications, including biosimilars, to their formularies.

Here are the top 5 biosimilar articles for the week of January 27, 2025.

Here are the top 5 biosimilar articles for the week of January 20, 2025.

Here are the top 5 biosimilar articles for the week of January 13, 2025.

Here are the top 5 biosimilar articles for the week of January 6, 2025.

Tiago Biachi, MD, PhD, emphasizes that biosimilars are vital for reducing financial toxicity and ensuring equitable, affordable access to advanced treatments in gastrointestinal (GI) cancer care, while calling for dynamic policies and greater cost awareness among clinicians.